Hospital Detox Shakeup and NFL Star Sidelined

Episode 17

0:00-14:27

Friday, October 23, 2026 In today's episode, Dr. Alok Patel (@alokpatelmd) & Adam Rose (@adjoro) cover a phase three trial of nicotinamide riboside in early Parkinson disease. Over 52 weeks, the supplement boosted NAD metabolism but showed no clinical benefit, raising questions for NAD boosting strategies. They also walk through a large hospital comparison of phenobarbital and diazepam for alcohol withdrawal, with similar stays and ventilation rates and fewer self directed discharges on phenobarbital, and why diazepam protocols may stay the course pending randomized trials. Plus: they also discuss national measles trends, FDA warning letters to Amazon and Walmart, and more. Coverage Timeline: (00:00) Intro (01:05) NR Supplement Trial for Parkinson's (03:01) NAD Supplements & Influencer Hype (04:49) Phenobarbital vs. Diazepam (07:30) Measles Surge in US (08:27) New Sunscreen Ingredient BEMT (09:01) Blood Clots Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production

Publisher

Medlines

Published

October 23, 2026

Duration

14 min

Format

Podcast

Category

Lifestyle · Medicine

Source

RSS feed

Host

Human Content, Inc.

M

Medlines

@medlines

#hospitaldetoxshakeup #nflstarsidelined #medicine #lifesciences

The Nile